GV joins $50 million round in Rome Therapeutics to research ‘junk DNA’ for cancer therapies

April 27, 2020

Rome Therapeutics'


Rome Therapeutics, which is using ML to explore the human genome and develop new treatments for cancer, has launched with $50 million in funding.Read More

You May Also Like…